NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Targeting vascular endothelial growth factor (VEGF) alone does not improve overall survival (OS) in recurrent glioblastoma (rGBM). The angiopoiein (Ang)-TIE2 system may play a role in tumor survival under VEGF inhibition. We conducted a phase 2, double-blinded, placebo-controlled trial of bevacizumab plus trebananib (a novel Fc fusion protein that sequesters Ang1/Ang2) over bevacizumab alone in rGBM.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cancer

Title: Cancer

Publisher: Wiley

ISSN (Electronic): 1097-0142

ISSN (Print): 0008-543X

Publication date (Electronic): June 15 2020

Volume: 126

Issue: 12

Affiliations

[1 ] Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.

[2 ] NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, Pennsylvania.

[3 ] Massachusetts General Hospital, Boston, Massachusetts.

[4 ] Toronto General Hospital, Toronto, Ontario, Canada.

[5 ] The University of Texas MD Anderson Cancer Center, Houston, Texas.

[6 ] University of Texas Southwestern Medical Center, Dallas, Texas.

[7 ] Northwestern University, Evanston, Illinois.

[8 ] Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

[9 ] University of Chicago Comprehensive Cancer Center, Chicago, Illinois.

[10 ] University of Wisconsin Hospital and Clinics, Madison, Wisconsin.

[11 ] Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin.

[12 ] University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.

[13 ] University of Kentucky, Lexington, Kentucky.

[14 ] University of Southern California, Los Angeles, California.

[15 ] North Shore University Health System, Evanston, Illinois.

[16 ] The US Oncology Network-Willamette Valley Cancer Institute, Eugene, Oregon.

[17 ] Baptist Hospital of Miami, Miami, Florida.

Article

Mid ID: NIHMS1582953

DOI: 10.1002/cncr.32811

PMC ID: 7245544

PubMed ID: 32154928

SO-VID: 0a21975a-dbb7-4593-9e63-a0e95228d122

History

Keywords: glioblastoma,angiogenesis,angiopoietin,bevacizumab,trebananib

Data availability:

Keywords: glioblastoma, angiogenesis, angiopoietin, bevacizumab, trebananib

Comments

Comment on this article

scite_

Cited by 16

See all cited by